Sangamo Therapeutics Statistics
Total Valuation
LON:0R1D has a market cap or net worth of GBP 113.22 million. The enterprise value is 102.33 million.
Market Cap | 113.22M |
Enterprise Value | 102.33M |
Important Dates
The next estimated earnings date is Friday, November 7, 2025.
Earnings Date | Nov 7, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
Current Share Class | 301.71M |
Shares Outstanding | n/a |
Shares Change (YoY) | +20.61% |
Shares Change (QoQ) | +16.65% |
Owned by Insiders (%) | n/a |
Owned by Institutions (%) | n/a |
Float | 295.14M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 1.90 |
PB Ratio | 7.91 |
P/TBV Ratio | 7.91 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | -2.21 |
EV / Sales | 1.71 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | -3.87 |
Financial Position
The company has a current ratio of 1.05, with a Debt / Equity ratio of 1.20.
Current Ratio | 1.05 |
Quick Ratio | 0.91 |
Debt / Equity | 1.20 |
Debt / EBITDA | n/a |
Debt / FCF | -0.65 |
Interest Coverage | -17.19 |
Financial Efficiency
Return on equity (ROE) is -292.47% and return on invested capital (ROIC) is -81.82%.
Return on Equity (ROE) | -292.47% |
Return on Assets (ROA) | -41.15% |
Return on Invested Capital (ROIC) | -81.82% |
Return on Capital Employed (ROCE) | -125.74% |
Revenue Per Employee | 325,886 |
Profits Per Employee | -252,502 |
Employee Count | 183 |
Asset Turnover | 0.86 |
Inventory Turnover | n/a |
Taxes
Income Tax | -140,871 |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -38.64% in the last 52 weeks.
Beta (5Y) | n/a |
52-Week Price Change | -38.64% |
50-Day Moving Average | 0.53 |
200-Day Moving Average | 0.92 |
Relative Strength Index (RSI) | 49.07 |
Average Volume (20 Days) | 73,186 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | 2.61 |
Income Statement
In the last 12 months, LON:0R1D had revenue of GBP 59.64 million and -46.21 million in losses. Loss per share was -0.21.
Revenue | 59.64M |
Gross Profit | -16.64M |
Operating Income | -45.80M |
Pretax Income | -46.35M |
Net Income | -46.21M |
EBITDA | -42.53M |
EBIT | -45.80M |
Loss Per Share | -0.21 |
Balance Sheet
The company has 27.99 million in cash and 17.12 million in debt, giving a net cash position of 10.86 million.
Cash & Cash Equivalents | 27.99M |
Total Debt | 17.12M |
Net Cash | 10.86M |
Net Cash Per Share | n/a |
Equity (Book Value) | 14.31M |
Book Value Per Share | 0.05 |
Working Capital | 1.63M |
Cash Flow
In the last 12 months, operating cash flow was -26.20 million and capital expenditures -212,401, giving a free cash flow of -26.42 million.
Operating Cash Flow | -26.20M |
Capital Expenditures | -212,401 |
Free Cash Flow | -26.42M |
FCF Per Share | n/a |
Margins
Gross margin is -27.89%, with operating and profit margins of -76.79% and -77.48%.
Gross Margin | -27.89% |
Operating Margin | -76.79% |
Pretax Margin | -77.72% |
Profit Margin | -77.48% |
EBITDA Margin | -71.32% |
EBIT Margin | -76.79% |
FCF Margin | n/a |
Dividends & Yields
LON:0R1D does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -20.61% |
Shareholder Yield | n/a |
Earnings Yield | -40.81% |
FCF Yield | -23.33% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | n/a |
Lynch Upside | n/a |
Graham Number | n/a |
Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
LON:0R1D has an Altman Z-Score of -21.84 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | -21.84 |
Piotroski F-Score | 4 |